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Background. Age-associated epigenetic changes are implicated in aging. Notably, age-
associated DNA methylation changes comprise a so-called aging “clock”, a robust 
biomarker of aging. However, while genetic, dietary and drug interventions can extend 
lifespan, their impact on the epigenome is uncharacterized. To fill this knowledge gap, we 
defined age-associated DNA methylation changes at the whole-genome single-nucleotide 
level in mouse liver, and tested the impact of longevity-promoting interventions, 
specifically the Ames dwarf Prop1df/df mutation, calorie restriction and rapamycin.  
 
Results. In wild type mice fed an unsupplemented ad libitum diet, age-associated 
hypomethylation was enriched at super-enhancers in highly expressed genes critical for 
liver function. Genes harbouring hypomethylated enhancers were enriched for genes that 
change expression with age. Hypermethylation was enriched at CpG islands marked with 
bivalent activating and repressing histone modifications and resembled 
hypermethylation in liver cancer.  Age-associated methylation changes are suppressed in 
Ames dwarf and calorie restricted mice, and more selectively and less specifically in 
rapamycin treated mice.  
 
Conclusions. Age-associated hypo- and hypermethylation events occur at distinct 
regulatory features of the genome. Distinct longevity-promoting interventions, 
specifically genetic, dietary and drug interventions, suppress some age-associated 
methylation changes, consistent with the idea that these interventions exert their 
 3 
beneficial effects, in part, by modulation of the epigenome. This study is a foundation to 
understand the epigenetic contribution to healthy aging and longevity and the molecular 
basis of the DNA methylation clock.    
 
Introduction 
Genetic, dietary and drug interventions can enhance longevity and suppress age-associated 
disease, such as cancer. Prominent genetic interventions that robustly extend longevity and 
healthspan in mammals include those that decrease growth hormone (GH) and insulin-like 
growth factor (IGF) signalling, for example Ames dwarf mice live more than 50% longer than 
their wild type siblings [1]. These diminutive mice result from a point mutation in a gene 
(Prop1df/df) that drives development of the pituitary gland, so that mutant mice are deficient in 
specific hormones.  The GH deficiency, in particular, has been shown to underlie their enhanced 
health span and extended lifespan.  Ames mice are highly insulin-sensitive, resistant to some 
stresses and the incidence of cancer is reduced [2-4]. Dietary and drug interventions that extend 
lifespan include calorie restriction (CR) and the mTOR inhibitor, rapamycin [5]. Like the Ames 
dwarf mutation, CR and rapamycin also suppress and/or delay the incidence of cancer [5-7]. A 
detailed understanding of how these interventions exert their beneficial effects is essential to 
develop strategies to promote healthy aging in humans [8]. Currently, these interventions are 
thought to exert their effects by related and interconnected effects on some or all of the 
following: genome stability, the epigenome, telomere attrition and/or function, protein quality 
control, mitochondrial function, nutrient sensing, cellular senescence, stem cell exhaustion, 
cellular stress responses and altered intercellular communication [9]. Of note, the effects of 
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longevity promoting interventions on the epigenome, a key determinant of cell phenotype, are 
poorly understood.  
Aging is associated with changes to the epigenome [10].  These changes include age-
associated accumulation of histone variants, for example histone H3.3 in neurons and macroH2A 
in lung, liver and muscle, as well as other chromatin-associated proteins and changes to histone 
and DNA modifications [11-13]. Aging also affects specific gene regulatory elements, such as 
enhancers, promoters and CpG islands [14-22]. Underscoring the importance of such age-
associated epigenetic changes, recent human studies have identified collections of specific CpGs 
whose age-associated change in methylation status in multiple tissues correlates strongly with 
chronological age. An advanced methylation age compared to actual chronological age is thought 
to reflect accelerated biological age, and is linked to increased mortality [23-27]. 
Age-associated epigenetic changes are not just biomarkers or passengers in the aging 
process, but can be causative in control of lifespan [28-30]. For example, in yeast, accumulation of 
H4K16ac at subtelomeric regions promotes replicative aging, while inactivation of the chromatin 
remodeler Iswi2p or the H3K36me2/3 demethylase Rph1p extends lifespan [28, 31, 32]. 
Decreased H3K4 methyltransferase activity can extend worm lifespan in a germline dependent 
manner [29]. In mice, muscle stem cells from old mice exhibit elevated repressive H3K27me3 at 
repressed histone genes [33], perhaps responsible for decreased proliferative potential of aged 
stem cells compared to young stem cells [34]. Mouse hematopoietic stem cells (HSCs) also exhibit 
changes in DNA methylation with age, including a small net hypermethylation both globally and 
at CpG islands [35, 36]. Some of these changes in aged cells are thought to promote expression of 
self-renewal genes and impair expression of differentiation genes, including lymphoid genes. This 
 5 
can contribute to the characteristic phenotypes of aged HSCs, such as increased number, 
decreased function and a predisposition to myeloid differentiation [35].  
Epigenetic changes linked to aging also impact specific diseases of aging, including cancer. 
While some age-associated epigenetic changes, such as increased abundance of histone 
modification H4K20me3 [10] and decreased H3K27me3 [37, 38], may activate tumor suppressor 
mechanisms and prevent cancer, others may be tumor promoting. Like cancer, aged tissue has 
been reported to exhibit global DNA hypomethylation and more focal hypermethylation at CpG 
islands [10]. Most notably, so-called bivalent gene promoters, marked with both activating 
H3K4me3 and repressing H3K27me3 (hence “bivalent”) in embryonal stem (ES) cells, acquire 
DNA methylation in aged tissues and are also methylated and stably silenced in cancer [14-18]. In 
ES cells, these bivalent-marked genes are thought to be poised for activation due to loss of the 
repressive H3K27me3 mark during stem and progenitor cell differentiation and development. By 
virtue of their pro-differentiation functions these genes tend to have tumor suppressor-like 
properties, meaning that their methylation and stable silencing may promote proliferation, self-
renewal and malignancy. In the hematopoietic system, some CpG islands progressively increase 
methylation from young to old to neoplasia, namely myelodysplastic syndrome (MDS) and 
ultimately acute myeloid leukemia [39]. Sf3b1, the mouse ortholog of a gene frequently mutated 
in human MDS, is methylated and underexpressed in aged mouse HSCs [35]. Hence, age-
associated methylation changes might predispose to transformation of aged cells, by promoting 
silencing of tumor suppressor genes.  
Given this strong and accumulating evidence that epigenetic events are important 
determinants of lifespan and predisposition to disease, we set out to ask whether genetic, dietary 
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and drug interventions that promote healthy aging and longevity suppress age-associated DNA 
methylation changes.  
 
Methods 
Ames dwarf mice were derived from a closed colony with a heterogeneous background (over 25 
years) at the University of North Dakota [40]. Dwarf mice (and corresponding wild type (WT)) 
were generated by mating either homozygous (df/df) or heterozygous (df/+) dwarf males with 
heterozygous females (df/+).  Non-genotypic intervention studies (rapamycin and CR) utilized 
genetically heterogeneous WT UM-HET3 mice bred at the University of Michigan.  One cohort was 
given encapsulated rapamycin (42 pmm) from 4 months of age, and another group a CR diet 
initiated at 4 months of age (these mice received 60% of the intake of their age-matched controls 
after a two week run-in period at 80%).  All cohorts contained 4 replicates (4 mice). Liver tissue 
was collected at 2 and 22 months of age and DNA isolated using DNeasy blood and tissue kit 
(Quagen). Hepatocellular carcinoma (HCC) is a relatively common disease of aging in mice. 
Hence, to avoid distortion of our data by neoplastic tissue, aged mice were sacrificed at 22 
months (before HCC is typically apparent) and livers with overt signs of neoplasia were excluded 
from analysis. Where WGBS-seq was performed (by BGI, Shenzen), samples underwent a 
standard protocol of sonication, DNA-end repair and ligation of methylated adapter sequences 
prior to bisulfite conversion using ZYMO EZ DNA Methylation-Gold Kit (Zymo Research) and then 
90 bp, paired-end sequencing on the Illumina Hi-Seq 4000 platform. Sequenced reads were 
aligned to reference genome (mm9) and methylation status of CpGs determined using Bismark 
and Bowtie2 [41, 42]. The bioinformatics process involved read quality assessment via FastQC, 
read trimming using the package Trim-Galore with alignment, read deduplication and 
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methylation context extraction via the Bismark suite [41]. CpG dyads were collapsed by 
combining the methylated and unmethylated scores at each dyad locus.  There are approximately 
42 million CpG loci in the mouse genome (mm9) – or 21.3 million CpG dyads.  We achieved 
sufficient coverage to represent between 94-96% of the dyads in the young and old, WT and 
Ames dwarf dataset, with a mean coverage of 6.96 methylation calls per site (four biological 
replicates per cohort (approximately 15-fold coverage per genome), to yield approximately 
1500Gbp of data (Additional File Supplementary Dataset 1: Table S1)).  Despite sequencing CR 
and rapamycin interventions data with reduced coverage, we still observe 86-89% of all 
mappable CpG dyads with a mean coverage of 4.37 reads per loci. To identify differentially 
methylated CpG sites, a two-tailed Fisher exact test (FET) was used with p-value correction using 
Benjimini-Hochberg (BH-) FDR function at a rate of 5% where coverage surpassed a threshold of 
10 overlapping reads.  To identify DMRs, we used a sliding window-based approach operating at 
a range of 500bp.  At each window, a two-tailed FET was performed to determine DMR 
significance alongside a chi-squared test of heterogeneity across the 4 mouse replicates within 
each cohort.  Both chi-squared and FET tests were multi-sample corrected using BH-FDR with 
DMRs selected on the basis of significant (p < 0.05) BH-FDR corrected FET score and non-
significant intra-cohort heterogeneity via the FDR corrected chi-squared test.  We then divided 
DMRs into hyper- and hypomethylated, based on positive or negative changes in their respective 
methylation relative to their control.  To determine the significance of the overlaps between 
regions or features, we used a permutation-based approach to assess significant enrichment over 
equally sized, randomly generated regions and calculated fold enrichments based on how these 
regions overlap, compared to an expected (random) model level of intersection. We validated 
findings using MeDIP-seq, an enrichment based assay that enriches methylated DNA fragments 
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via immunoprecipitation with anti-methyl-cytosine antibodies [60]. Additional details, including 
RNA- and ChIP-seq analysis information, available in Additional File Supplementary Methods). 
 
Results 
The epigenomes of wild type and Ames dwarf mice diverge with age.   To investigate the 
relationship between age-associated epigenetic changes and healthy aging and longevity, we first 
set out to compare the DNA methylome of liver from young and old male WT and long-lived Ames 
dwarf mice. We selected liver for this study because our previous studies showed differences in 
liver in expression of DNMTs between WT and Ames mice and young and old mice [43]. Also, a 
single cell type, the hepatocyte, comprises ~80% of liver mass, and the epigenome of mouse liver 
has been extensively characterized, thereby aiding downstream analysis of the methylome in the 
context of the wider epigenetic landscape. We performed whole genome bisulfite sequencing 
(WGBS-seq) on the livers of young adult (2 months of age) and old (22 months of age) Ames 
dwarf and WT mice. We found that global levels of methylation across all CpGs in the genome 
were highly similar between all age groups, mouse genotypes and replicates (Figure 1a). This was 
also apparent from viewing whole-chromosome methylation profiles on the UCSC genome 
browser (Figure 1b). However principal component analysis (PCA) of the data (% methylation 
per CpG) suggested that local differences in methylation were present, as cohorts separated well 
on the 1st and/or 2nd principal components (12.38% and 7.64% of the respective cumulative 
variance) (Figure 1c).  
Previous studies showed that epigenomes become more divergent with age [44]. Therefore, 
we set out to assess differences between WT and Ames dwarf mice at 2 months and 22 months of 
age. We determined those CpGs differentially methylated between genotypes (i.e. between WT 
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and Ames dwarf mice (gCpGs)). This was performed separately in both the young and old mice, 
using a Fisher’s Exact Test method at 5%FDR (Methods). In dwarf mice, compared to WT mice, 
approximately 10x more CpGs were hypermethylated than were hypomethylated (Figure 1d). 
Strikingly, we observed a larger number of significantly hypermethylated gCpGs (Figure 1d) in 
the older mice as compared to the young, suggesting that the WT and Ames mice exhibit more 
epitype differences with age. These differences were also visualised by identifying all 
differentially methylated regions (gDMRs) for both the young and the old mice, using a dynamic 
500bp sliding window and Fisher’s Exact Test method at 5% FDR, and also removing any DMRs 
that are not consistent across all 4 replicates (Methods) (Figure 1e and Additional File 
Supplementary Statistical Data: Table 1e). We observed a significant increase in hypermethylated 
gDMRs, while the increase in hypomethylated gDMRs was not significant (Figure 1e and 
Additional File Supplementary Statistical Data: Table 1e). The consistency of the gDMRs across all 
four replicates within each cohort was confirmed in both gDMR heatmaps (Figure 1f) and kernel 
smoothed methylation plots of representative gDMRs (Figure 1g). Together, these data establish 
that between the Ames and WT mice there are more than 20,000 DMRs, and the number of these 
epigenotype differences increases markedly with age.  
 
The Ames dwarf epigenome appears more stable and buffered against age-associated 
hypomethylation. To further investigate these age-associated epigenotype differences between 
the WT and dwarf mice, we characterised age-associated differentially methylated CpGs (i.e. CpGs 
whose methylation status changes with age in either WT or Ames dwarf mice (aCpGs)) in both 
the WT and dwarf mice, using a Fisher’s Exact Test method at 5%FDR (Methods). Strikingly we 
observed roughly three times more significant aCpGs in the WT than the dwarf mice (Figure 2a), 
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suggesting that the methylome of dwarf mice is more stable through chronological aging. 
Similarly, we detected less than half the number of aDMRs in dwarf mice compared to WT mice 
(Figure 2b and Additional File Supplementary Statistical Data: Table 2b). Changes in the aDMRs 
were consistent across all four replicates within each cohort, as confirmed by aDMR heatmaps 
(Figure 2c, d) and representative kernel smoothed methylation plots (Figure 2e). Although we 
observed significantly more aDMRs in the WT than the dwarf mice, the magnitude of the 
methylation change per DMR was comparable in the WT and dwarf (Figure 2f). To confirm these 
aDMR loci in other mouse cohorts and strains, we performed WGBS-seq of whole liver from 2 
month and 22 month of age female UM-HET3 mice from the NIA Intervention Testing Program 
(ITP) cohorts (4 mouse replicates per age group, approximately 5x coverage per replicate) 
(Additional File Supplementary Dataset 2: Table S2). Global methylation was comparable to Ames 
dwarf and corresponding WT and, again, between young and old (compare Figures 1a and S1a). 
However, PCA again separated the young and old UM-HET3, indicative of their differential 
methylation (Figure S1b). Hence, aDMRs were identified between young and old UM-HET3 mice 
(Methods). The extent of overlap of the two sets of WT hypomethylated aDMRs (i.e. the WT used 
for comparison to Ames dwarf throughout and WT UM-HET3 (see Methods)) was much greater 
than expected from random overlap and highly significant. The same was the case for the two 
sets of hypermethylated aDMRs. However, there was minimal overlap between hypermethylated 
and hypomethylated aDMRs (Figure 2g). In sum, aging of the liver generates thousands of 
discrete aDMRs. Significantly, the epigenome of WT mice exhibits many more such regions than 
that of Ames dwarf mice, suggesting that the Ames dwarf epigenome is more stable with 
chronological age than the wild type epigenome.  
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While many aDMRs were restricted to WT mice, other aDMRs were restricted to Ames mice 
or were shared by both genotypes (Figure S1c). Plots of mean percent methylation per mouse 
liver sample at each subset of DMR (i.e., WT hypermethylated aDMRs (Figure S1d), dwarf 
hypermethylated aDMRs (Figure S1e) and hypermethylated aDMRs shared between WT and 
dwarf (Figure 2h) confirmed the DMR subsets and consistency between mouse replicates (Figure 
2h,i and Figure S1d-g). For example, at shared hypermethylated aDMRs, methylation increased 
comparably with age in both WT and dwarf (Figure 2h). The methylation changes at 
hypomethylated aDMRs were particularly interesting. At the hypomethylated aDMRs restricted 
to WT mice, the young and old Ames mice both showed methylation comparable to the young WT 
(Figure S1f), while at the hypomethylated aDMRs restricted to the Ames mice, the young and old 
WT mice both showed methylation comparable to the older Ames mice (Figure S1g). At shared 
hypomethylated aDMRs, while the magnitude of the change was comparable between WT and 
Ames, the dwarf mice showed consistently higher methylation than the WT in both age groups 
(Figure 2i). This phenomenon was also apparent in the population of individual aDMRs, which 
showed higher methylation in dwarf in both young and old mice (i.e. below right of the 45° 
diagonal in both plots), and an age-associated loss of methylation in both WT and dwarf (i.e. 
closer to zero on both x and y axes in old) (Figure S1h).   At representative shared 
hypomethylated aDMRs, methylation declined with age in both WT and dwarf, but began at 
higher levels in the young dwarf  (Figure 2j). In sum, in dwarf mice, hypomethylated aDMRs were 
biased towards a higher methylation level. This is most notable at hypomethylated aDMRs shared 
between WT and Ames dwarf, where the latter exhibited a higher initial level of methylation in 




Hypomethylated aDMRs are enriched at intragenic enhancers in highly expressed liver-
specific genes. Next, we set out to define the location of the hypomethylated aDMRs across the 
genome. First, we asked how the WT and dwarf hypomethylated aDMRs are distributed across a 
collection of genomic features. Although there were approximately twice as many 
hypomethylated aDMRs in WT mice than Ames mice (Figure 2b and 3a), the proportionate 
distribution of these aDMRs across features of the genome was very similar (Figure 3a). Most 
commonly, the hypomethylated aDMRs overlap genes (~60%) and introns (~50%), although 
they are only modestly enriched at these features, relative to the abundance of these features in 
the genome (Figure 3a). Least commonly, they overlapped CpG islands (<1%) and LINE elements 
(~5%), and were moderately depleted at these features (Figure 3a). To further investigate, we 
took advantage of the many publicly available datasets for mouse liver and expanded this 
distribution analysis to include several ENCODE adult mouse liver histone modification ChIP-seq 
datasets (Figure 3a and Figure S2a and Additional Files Supplementary Datasets 3 and 4: Tables 
S3 and S4 respectively). Strikingly, we observed that ~55% and ~40% (Figure 3a) of all 
hypomethylated aDMRs overlapped the enhancer modifications H3K4me1 and H3K27ac, with an 
enrichment of 7-9 fold (p<0.001)(Figure 3a). There was a more modest overlap and enrichment, 
or even depletion, at other histone modifications, notably the gene body modification H3K36me3 
and the repressive mark H3K27me3 (Figure 3a).  In line with this enrichment at H3K4me1 and 
H3K27ac, there was marked overlap and enrichment at designated mouse liver enhancers, 
regions marked by both H3K4me1 and H3K27me3 (“Enhancers”, Figure 3a). Of the ~47,000 
identified mouse liver enhancers, 8,230 and 4,702 contained a hypomethylated aDMR in WT and 
dwarf respectively (Figure 3b), corresponding to a substantial fraction of all enhancers. Of these a 
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significant number (2,037) were hypomethylated in both genotypes (fold enrichment of 153, 
p<0.001 in Figure 3b). As for shared hypomethylated aDMRs generally (Figure 2i), these shared 
hypomethylated enhancers are apparently buffered from methylation loss in the Ames mice 
(Figure 3c, d). 6193 enhancers contained hypomethylated aDMRs in WT mice only (Figure 3b). 
These showed more marked loss of methylation in aged WT mice compared to aged dwarf mice 
(Figure 3e).  
Since the majority of the hypomethylated enhancers are contained within genes (Figure 3a 
and Figure S2b), we also assessed the relationship between enhancer hypomethylation and gene 
expression, determined by RNA-seq (Additional File Supplementary Dataset 5: Table S5). The 
methylation loss per enhancer CpG was independent of expression of the gene harbouring the 
enhancer (Figure S2c). However, hypomethylated enhancers appeared more abundant, longer 
and to cover a greater fraction of the gene in highly expressed genes compared to lowly 
expressed genes (Figure 3f and S2d, e). Consistent with their high level of expression in liver, in 
both WT and dwarf mice the genes harbouring hypomethylated enhancers were highly enriched 
for liver specific genes (Figure S2f). Moreover, of 30 publicly available adult mouse liver 
transcription factor ChIP-seq datasets (Figure S2a), the factors most enriched for binding to 
hypomethylated aDMRs in both genotypes included key regulators of liver function (e.g., CEBPB, 
GR (NR3C1), RXRA, PPARA, CEBPA, HNF3A and HNF4A) (p<0.001)(Figure 3a). Recently, super-
enhancers have been defined as clusters of enhancers that are densely bound by master 
transcription regulators and control expression of critical tissue specific genes [45]. Remarkably, 
enhancers hypomethylated during aging were greatly enriched at such super-enhancers (Figure 
3g and Additional File Supplementary Statistical Data: Table 3g). Many of these trends were 
exacerbated in WT mice compared to Ames dwarf mice (Figure 3f, g and S2d, e). There was a 
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significant overlap of hypomethylated genic enhancers and changes in expression of linked genes, 
although the vast majority of genes containing hypomethylated enhancers did not significantly 
alter expression (Additional File Supplementary Dataset 6: Table S6). We conclude that 
hypomethylated aDMRs are most abundant at genes, introns and enhancers, and 
disproportionately enriched at genic super-enhancers in highly expressed genes known to play a 
key role in liver function. Although the distribution of hypomethylated aDMRs is similar across 
the WT and dwarf epigenomes, WT mice harbor a greater number of hypomethylated genes and 
enhancers and the potentially disruptive effects of hypomethylation [46] are seemingly buffered 
by a higher level of methylation in young dwarf mice. 
 
Hypermethylated aDMRs are enriched at bivalent CpG islands. We then wanted to 
characterize and determine the location of hypermethylated aDMRs in the two genotypes of mice. 
Taking the same approach as for the hypomethylated aDMRs (Figure 3a), we asked how the 
hypermethylated aDMRs are spatially distributed and enriched across a range of genomic 
features, histone modifications and transcription factors (Figure 4a and Figure S3a). Like 
hypomethylated aDMRs, there were more hypermethylated aDMRs in WT mice than Ames mice 
(Figure 2b and Additional File Supplementary Statistical Data: Table 2b). However, in contrast to 
hypomethylated aDMRs, the distribution of hypermethylated aDMRs appeared different between 
the two genotypes. This was initially apparent in a notable disparity between fold enrichment of 
hypermethylated aDMRs in WT and dwarf mice; at many features these aDMRs tended to show 
lower fold enrichment or even depletion in WT mice, particularly at transcription factor binding 
sites (Figure 4a and S3a). Closer analysis showed that, while hypomethylated aDMRs were 
similarly distributed in WT and dwarf between regions marked or unmarked by histone 
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modifications and transcription factors, hypermethylated aDMRs in WT mice were 
disproportionately at regions lacking histone modifications and transcription factors (Figure 4b 
and S3b). Most of these WT-specific hypermethylated aDMRs were at regions of the genome that 
are relatively highly methylated even in young mice (Figure S3c).  
Across more richly annotated regions of the genome, hypermethylated aDMRs were 
distributed similarly in WT and Ames mice. In both genotypes, hypermethylated aDMRs showed 
the greatest overlap with genes and introns, although like hypomethylated aDMRs this was not 
enriched considering the abundance of these features in the genome (Figure 4a). There was some 
enrichment of hypermethylated aDMRs at H3K27ac and H3K4me1-marked enhancers, although 
less so than for hypomethylated aDMRs (Figure 3a and 4a). However, in marked contrast to 
hypomethylated aDMRs, hypermethylated aDMRs showed large enrichment at CpG islands and 
H3K4me3 and H3K27me3 marked bivalent chromatin (p<0.001)(Figure 4a). There was 
substantial overlap between hypermethylated aDMRs at CpG islands and bivalent chromatin (fold 
enrichment 1,302 and p<0.001) (Figure 4c and Additional File Supplementary Statistical Data: 
Table 4c), meaning that hypermethylated aDMRs were enriched at bivalent marked CpG islands 
(Figure 4d). Hypermethylated bivalent regions overlapped significantly between genotypes, 
although there were approximately 50% more in the WT mice than Ames mice (Figure 4e and 
Additional File Supplementary Statistical Data: Table 4e). Interestingly, genes linked to these 
bivalent CpG islands tended to be expressed at relatively low levels (Figure 4f), and there was no 
enrichment for change in expression at these genes (Additional File Supplementary Dataset 6: 
Table S6). Gene ontology analysis showed that many of these bivalent CpG islands are linked to 
developmentally important genes that establish cell identity, similar to bivalent CpG islands in ES 
cells [47] (Figure S3d). In sum, hypermethylated aDMRs are enriched at bivalent CpG islands, 
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often of lowly expressed genes implicated in control of development and cell identity, and age-
associated methylation of these islands is substantially more frequent in WT mice compared to 
Ames dwarf mice.  
To confirm these key findings by an alternative methodology, we performed MeDIP-seq (a 
whole genome sequencing-based method that isolates methylated DNA sequences using an 
antibody to 5-methyl-cytosine (5-mC) [48]) on a single replicate of young and old WT and Ames 
dwarf mice.  This allowed us to plot the relative enrichment of methylated DNA reads at a set of 
regions, in this case the hypomethylated enhancer aDMRs and hypermethylated bivalent aDMRs 
that are shared between WT and Ames dwarf mice (Figure 3b and 4e).  This analysis confirmed a 
gain of methylation at hypermethylated bivalent regions and a decrease in methylation at 
hypomethylated enhancers (Figure S4a, b and Additional File Supplementary Statistical Data: 
Table S4a and S4b).  Although this MeDIP-seq method cannot resolve methylation status at the 
single nucleotide level and our analysis of this data is limited to a single replicate, this alternative 
approach clearly validates key methylation changes in WT and Ames dwarf mice.  
 
Ames dwarf mice are resistant to cancer-like methylation changes during aging. Bivalent 
CpG islands marked with H3K4me3 and H3K27me3 in ES cells tend to be DNA methylated in aged 
tissues and methylated and silenced in cancer [14-18], suggesting that age-associated DNA 
methylation can be a precursor to methylation and stable silencing in cancer. Therefore, we 
wanted to assess whether CpG islands methylated with age in mouse liver are also methylated on 
progression towards liver cancer and, if so, whether this trend was suppressed in cancer-
resistant Ames dwarf mice. To do this, we analyzed DNA methylation data, obtained by 
methylated DNA immunoprecipitation (MeDIP) followed by array hybridization, from the late 
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precancerous stages of HCC development in 12-month old Mdr2/Abcb4-knockout (Mdr2-KO) 
male FVB strain mice, a well characterized model of chronic inflammation-mediated HCC [49, 50]. 
These mice typically exhibit chronic hepatitis from 2 months and HCC at 12-18 months. 
Enhancers that were hypomethylated in aged WT mice were comparably methylated in WT and 
Mdr2-KO mice (Figure 5a and Additional File Supplementary Statistical Data: Table 5a). In 
contrast, enhancers and bivalent CpG islands that were hypermethylated in aged WT mice also 
tended to be hypermethylated in Mdr2-KO mice (Figure 5b,c and Additional File Supplementary 
Statistical Data: Tables 5b and 5c). This phenomenon was particularly marked at bivalent CpG 
islands. The same marked trend was also apparent at enhancers and bivalent CpG islands 
methylated with age in dwarf mice (Figure 5d-f and Additional File Supplementary Statistical 
Data: Tables 5d-f).  As noted previously, however, there were fewer such aDMRs in dwarf mice 
compared to WT mice (Figure 2b). These data confirm that adult liver bivalent CpG islands that 
are methylated during aging also tend to be methylated in pre-cancerous liver.  
 
Age-associated DNA methylation changes are also suppressed by calorie restriction and 
rapamycin. As well as genetic interventions, dietary and drug interventions also promote 
longevity, healthy aging and suppression of cancer. To test whether dietary and drug 
interventions also suppress age-associated DNA methylation changes, we examined livers from 
female UM-HET3 mice treated with encapsulated rapamycin (42mg/kg of food) from 4 months to 
22 months of age and female mice on a CR diet from 4 months to 22 months of age [51-54]. We 
performed WGBS-seq on DNA from whole liver, 4 replicates per cohort, approximately 5x 
coverage per sample (Additional File Supplementary Dataset 2: Table S2). As controls for these 
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UM-HET3 mice, we analyzed female UM-HET3 mice of 2 months and 22 months of age fed ad 
libitum (ad lib) (Figure 2g and S1a, b). 
 The mean global methylation level of each cohort was very similar (72.72% - 73.35%) and 
also very similar to the mean global methylation of the Ames dwarf mice and corresponding WT 
(compare Figure 1a to Figure 6a). To begin to assess the impact of CR and rapamycin on age-
associated methylation changes, we compared hypomethylated and hypermethylated aDMRs 
between young and old UM-HET3 mice (both ad lib) with the same regions in rapamycin-treated 
and CR old mice. At hypomethylated aDMRs, methylation loss was suppressed by CR and to a 
lesser extent by rapamycin (Figure 6b and Supplementary Figure S5a-d and Additional File 
Supplementary Statistical Data: Tables 6b and S5a-d). At hypermethylated aDMRs, methylation 
gain was also suppressed by CR, but not significantly by rapamycin (Figure 6c and 
Supplementary Figure S5a, e-g and Additional File Supplementary Statistical Data: Tables S5a, e-
g). At these regions, the effect of rapamycin was not significant in the whole population of 
hypermethylated aDMRs (Figure 6c and Supplementary Figure S5a and Additional File 
Supplementary Statistical Data: Table S5a), but was detectable in some individual aDMRs 
(Supplementary Figure S5f, g).  
To assess where in the genome rapamycin and CR suppress age-associated methylation 
changes, we generated clustered feature interaction maps depicting the genomic distribution of 
regions where methylation changes were suppressed by rapamycin and CR. CR suppressed age-
associated changes widely, including at genes, enhancers and CpG islands (Figure 6d, e and 
Additional File Supplementary Statistical Data: Tables 6d, e). Rapamycin suppressed age-
associated changes at a smaller number of genes, enhancers and CpG islands (Figure 6f, g and 
Additional File Supplementary Statistical Data: Tables 6f, g). When averaged across a “composite” 
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of all enhancers hypomethylated with age, the suppression was similarly more marked by CR 
than rapamycin (Figure 6h). When averaged across all hypermethylated bivalent regions, the 
suppression by CR was readily apparent but modest, whereas the suppression by rapamycin was 
undetectable (Figure 6i). In sum, while both CR and rapamycin suppressed age-associated 
hypomethylation at enhancers, at least under these protocols CR was more efficient than 
rapamycin. CR also suppressed hypermethylation of some bivalent regions and CpG islands, while 
at these regions the effect of rapamycin was detectable at a minority of regions but not in all 
regions combined.  
In addition to suppressing age-associated methylation events, closer analysis revealed that 
both CR and rapamycin caused a number of hypo and hypermethylation events that did not 
reflect a suppression of age-associated changes (Figure S5h).  However, rapamycin caused 
substantially more of these than did CR. These non-age related methylation changes were widely 
distributed, including at genes, bivalent CpG islands and enhancers (Figure S5h).  
 
Discussion 
Here we have comprehensively mapped age-associated changes in DNA methylation across all 42 
million CpGs of the genome by WGBS-seq of young and old mouse liver. In analysis and 
interpretation of our data, we have made extensive use of gene expression data and the many 
epigenomic data sets publicly available for mouse liver. Although we failed to observe global 
change in DNA methylation, e.g. a global hypomethylation, we did observe thousands of age-
associated changes across discrete regions of the genome. The greatest number of such gains and 
losses of methylation occur at genes and introns, although the number of these changes is in 
proportion to the fraction of the genome occupied by those features. Instead, losses of 
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methylation are most enriched at genic enhancers, including super-enhancers, within genes 
highly expressed in liver, and gains of methylation are most enriched at bivalent CpG islands. In 
sum, age-associated changes in DNA methylation are most abundant and/or enriched at various 
important functional and regulatory regions of the genome.  
What is the cause of these age-associated changes? It is tempting to speculate that age-
associated changes are linked to the dynamic nature of these regulatory and functional regions. 
These dynamic regions are maintained at a steady state equilibrium that may change with age. 
Expressed genes and enhancers are thought to be particularly dynamic regions of the epigenome 
[55]. More specifically, age-associated changes in DNA methylation might be linked to age-
associated changes in expression of the cellular machinery that directly controls DNA 
methylation, such as DNMTs and TETs. Indeed, we have previously shown an age-associated 
increase and decrease in expression of DNMT3a and DNMT1 respectively, in mouse liver [43]. 
Alternatively, age-associated changes in methylation might result from changes in metabolic 
substrates and cofactors important for activity of DNMTs and TETs, such as S-
adenosylmethionine (SAM) and -ketoglutarate respectively [56]. However, there must also be 
additional sequence and/or epigenetic determinants of methylation gains and losses to explain 
why some regions, such as bivalent CpG islands, gain methylation whereas others, such as 
enhancers, lose methylation with age.  
What is the consequence of these age-associated changes in methylation? Losses of 
methylation at enhancers are only weakly linked to changes in expression of linked genes, and 
some genes increase and others decrease in expression. Recent studies suggested that DNA 
methylation of enhancers is required for their functional integrity [46, 57]. So, while age-
associated loss of methylation at enhancers in these moderately old mice (22 months of age) is 
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only modestly linked to changes in gene expression, it is conceivable that this methylation loss is 
a precursor to more dramatic changes in methylation and expression in very old mice or perhaps 
after tissue stress. In contrast to enhancers, gains of DNA methylation at bivalent CpG islands are 
not enriched for changes in gene expression. Most of these genes are expressed at comparatively 
low levels even in normal young tissue, and a gain of methylation at the promoter CpG island is 
not expected to increase their expression. Importantly, however, age-associated changes at 
bivalent CpG islands are linked to hypermethylation in cancer, suggesting that age-associated 
gain in methylation can be a precursor to cancer, for example by blocking activation of pro-
differentiation and development genes, as proposed previously [14, 17].  
Age-associated changes in DNA methylation are suppressed by genetic, dietary and drug 
interventions that extend lifespan and delay/suppress the incidence of cancer, specifically the 
Prop1 mutation in the Ames dwarf mouse, CR and rapamycin [1, 5]. Each of these interventions 
suppresses age-associated changes in methylation at genes, enhancers and bivalent CpG islands. 
Consistent with the aforementioned proposal that age-associated methylation changes are linked 
to control of the DNA methylation machinery and/or its metabolic regulators, Ames dwarf mice 
do display atypical methionine metabolism, methionine being a source of the SAM that is 
required for DNA methylation. Components of this amino acid pathway are upregulated in Ames 
mice leading to higher enzyme activities, including of glycine N-methyltransferase (GNMT), an 
enzyme that converts SAM to S-adenosyl-homocysteine and sarcosine. Moreover, the 
methyltransferase enzymes important in DNA methylation and methionine metabolism are 
affected by the presence or absence of GH. Methionine flux assays confirm the enhanced enzyme 
activities demonstrating that transmethylation and transsulfuration are markedly elevated in 
dwarf mice [58, 59]. Thus, elevated GNMT in Ames dwarf mice might depress age-associated 
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methylation of CpG islands, perhaps contributing to delayed cancer incidence [2, 3]. Similarly CR 
and rapamycin might suppress the incidence of cancer [5-7], at least in part, by suppressing 
methylation of bivalent CpG island promoters. Aside from cancer suppression, the other shared 
benefits of these genetic, dietary and drug interventions for maintenance of tissue and systemic 
function into old age might depend on suppression of super-enhancer hypomethylation and so 
preservation of tissue specific enhancer integrity, gene expression programs and tissue function 
[46]. Typically, the effect of CR on the epigenome was greater than rapamycin, in line with the 
greater extension of lifespan by CR than rapamycin, at least under the protocols tested here [53, 
54].  
Notwithstanding the more efficient suppression of age-associated epigenetic changes by CR, 
the epigenetic effects of CR and rapamycin were not identical and this might further underlie 
some of the differences between them that have been noted in previous studies, for example in 
endocrine and metabolic phenotypes and gene expression profiles [53, 60]. Of note, rapamycin in 
particular appears to induce additional changes unrelated to age-associated changes. While both 
CR and rapamycin induced these non age-related effects, this effect was much more marked for 
rapamycin. These non age-related epigenetic changes include gains of methylation at genes, 
enhancers and CpG islands and losses of methylation at genes and enhancers. Conceivably, such 
non age-related effects of rapamycin in liver and other tissues may contribute to at least some of 
the well-documented harmful side-effects of rapamycin, such as glucose intolerance, increased 
incidence of testicular degeneration and cataracts [52, 53]. Detrimental effects of rapamycin-like 
drugs, including dyslipidemia, hyperlipidemia and risk of diabetes, have also been noted in 
humans [61, 62]. Of course, such adverse consequences of rapamycin might also have a non-
epigenetic basis. Regardless, this study is a first comparison of the effect of diverse genetic, 
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dietary and drug interventions on the epigenetic landscape, and a foundation for understanding 
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Figure Legends.  
Figure 1. The epigenomes of wild type and Ames dwarf mice diverge with age.  a) Global 
percent methylation per liver sample, for 2 month of age wild type (WTY), 22 month wild type 
(WTO), 2 month Ames dwarf (DY) and 22 month Ames dwarf (DO) mice. All P>0.05 (two tailed t-
test on arcsine transformed proportions). b) UCSC genome browser trace of percent methylation 
over chromosome 1, showing pooled WTY (light blue), WTO (dark blue), DY (light red), DO (dark 
red) replicate tracks. c) Principal component analysis of CpG percent methylation, for WTY (light 
blue), WTO (dark blue), DY (light red), DO (dark red) liver samples. PC1 (Proportion of variance: 
12.38%)" and to y-axis "PC2 (Proportion of variance: 7.64%). d) Bar chart of the number of 
significantly differentially methylated CpGs (5% FDR, Fisher’s Exact test) between 4 pooled WT 
and 4 pooled Ames dwarf replicates (gCpGs), in liver of 2 month (young) and 22 month (old) 
mice. Hyper and hypo-methylated gCpGs are higher and lower in Ames dwarf mice, respectively.  
e) As d), however showing significantly differentially methylated regions (gDMRs)(5% FDR, 
Fisher’s Exact test, 500bp windows). Regions of heterogeneity (chi-squared test <0.05) across the 
4 replicates in each cohort removed. DY-WTY vs DO-WTO hyper, p<0.05 (marked with *). See also 
Additional File Supplementary Statistical Dataset. f) Heatmaps of the percent methylation across 
all 2 month (left) and 22 month (right) gDMRs. Replicate samples (4 mouse livers) are in rows 
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and the gDMRs columns. The intensity of the heatmap represents column scaled % methylation 
(Z-score), with value ranging from lower to higher methylation as blue to yellow.  g) Kernel 
smoothed line plots of selected gDMRs, +/- 5kb. WTY, DY, WTO and DO replicates are 
represented by solid blue, solid red, dashed blue and dashed red lines respectively. DMRs are 
shown in pink and CpGs black. 
 
Figure 2. The Ames dwarf epigenome appears more stable and buffered against age-
associated hypomethylation. a) Bar chart of the number of significantly differentially 
methylated CpGs (5% FDR, Fisher’s Exact test) between 2 month and 22 month WT (WT) and 
between 2 month and 22 month Ames dwarf (dwarf) mice. Hyper and Hypo-methylated aCpGs 
are higher and lower in 22 month mice respectively. b) Bar chart of the number of significantly 
differentially methylated regions (aDMRs)(5% FDR, Fisher’s Exact test, 500bp windows), 
between 2 months and 22 month mice, for WT and Ames dwarf mice. Regions of heterogeneity 
(chi-squared test <0.05) across the 4 replicates in each cohort removed. Significance (empirical 
p-value) at p < 0.05 is indicated with *. See also Additional File Supplementary Statistical Dataset. 
c) Heatmap of the % methylation across all 2 month (DY) versus 22 month (DO) Ames dwarf 
differentially methylated regions (aDMRs). Replicate samples (4 mouse livers) are in rows and 
the aDMRs columns. The intensity of the heatmap represents column scaled % methylation (Z-
score), with value ranging from lower to higher methylation as blue to yellow.  d) Heatmap of the 
% methylation across all 2 month (WTY) versus 22 month (WTO) WT differentially methylated 
regions (aDMRs). Replicate samples (4 mouse livers) are in rows and the aDMRs columns. 
Columns are scaled using Z-scores. The intensity of the heatmap represents Z-score, with value 
ranging from negative to positive as blue to yellow. e) Kernel smoothed line plots of selected 
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aDMRs, +/- 5kb. WTY, 2 month dwarf (DY), WTO and 22 month dwarf (DO) replicates are 
represented by solid blue, solid red, dashed blue and dashed red lines respectively. DMRs are 
shown in pink and CpGs black. f) Histogram of the difference in mean % methylation per DMR 
(across all samples), between 22 and 2 month mice (O-Y), versus number of aDMRs. Showing WT 
aDMRs (red) and dwarf aDMRs (blue).  g) Bar chart showing ratio of observed/expected 
(random) overlap between WT (from panels a-d) and UM-HET3 aDMRs. Hyper and Hypo-
methylated aDMRs are higher and lower in old mice respectively. Significance (empirical p-value) 
at p < 0.001 is indicated with **. h) Mean % methylation per replicate across all hypermethylated 
aDMRs common to both WT and Ames dwarf mice (shared). WTY, WTO, DY and DO mice are light 
blue, dark blue, light red and dark red respectively. WTY vs WTO and DY vs DO at p < 0.001 
indicated with ** (two tailed t-test on arcsine transformed proportions). i) As h), however 
showing shared hypomethylated aDMRs. WTY vs WTO, DY vs DO, WTO vs DO all P<0.001 
indicated with ** and WTY vs DY P<0.05 indicated with * (two tailed t-test on arcsine 
transformed proportions). j)  Kernel smoothed line plots of selected aDMRs common to both WT 
and dwarf mice, +/- 5kb. Pooled replicates for WTY, DY, WTO and DO are represented by solid 
blue, solid red, dashed blue and dashed red lines respectively. DMRs are shown in pink and CpGs 
black. 
 
Figure 3. Hypomethylated aDMRs are enriched at intragenic enhancers in highly 
expressed liver-specific genes. a) Clustered feature interaction maps of spatial overlap 
between hypomethylated aDMRs (columns) and a selection of genomic, histone and transcription 
factor features (rows), showing WT (WT)(left) and dwarf (D)(center left) aDMRs. Red indicates 
an overlap between aDMR and feature and blue no overlap. Interaction map x axes are scaled by 
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number of aDMRs. The % overlap (center right) and fold enrichment observed/expected 
(random) overlap (right)(units of fold) for each feature is given. b) Venn diagram of the overlap 
between enhancers that contain hypomethylated aDMRs in WT and Ames dwarf mice. 
Enrichment of overlap obs/exp 153-fold, P<0.001. c) Mean % methylation per replicate across 
enhancers that contain hypomethylated aDMRs in both WT and dwarf mice. For 2 month WT 
(WTY)(light blue), 22 month WT (WTO)(dark blue), 2 month dwarf (DY)(light red) and 22 month 
dwarf (DO)(dark red) mice. WTY vs WTO, DY vs DO, WTO vs DO  all P<0.001  (indicated with **) 
and WTY vs DY P<0.05 (indicated with *) (two tailed t-test on arcsine transformed proportions). 
d) Kernel smoothed line plots of selected enhancers overlapping hypomethylated aDMRs, +/- 
5kb. Replicates for WTY, DY, WTO and DO are represented by solid blue, solid red, dashed blue 
and dashed red lines respectively. DMRs are shown in pink and CpGs black. H3K4me1 and 
H3K27ac enrichment (ChIP-seq) is indicated. e) Heatmap of the percent methylation across all 
enhancers containing hypomethylated aDMRs unique to WT mice (6,193 regions from Figure 3b). 
Replicate samples (4 mouse livers) are in columns and the aDMRs rows. The intensity of the 
heatmap represents row scaled % methylation (Z-score), with value ranging from lower to higher 
methylation as blue to red.  f) Mean number of enhancer overlapping hypomethylated aDMRs per 
gene for WT (Blue) and Ames dwarf (Red). Genes are split into quartiles by expression (Q1 = 
highest, Q4 = lowest). Unexpressed genes (FPKM = 0) are given (U). g) Observed and expected 
overlap (in base pairs) of hypomethylated DMRs (WT, WT only; dwarf, dwarf only; shared, 
shared between WT and dwarf) with super-enhancers. P<0.01 indicated by **. 
 
Figure 4. Hypermethylated aDMRs are enriched at bivalent CpG islands. a) Clustered feature 
interaction maps of spatial overlap between hypermethylated aDMRs (columns) and a selection 
 29 
of genomic, histone and transcription factor features (rows), showing WT (WT)(left) and dwarf 
(D)(center left) aDMRs. Red indicates an overlap between aDMR and feature and blue no overlap. 
Interaction map x axes are scaled by number of aDMRs. The % overlap (center right) and fold 
enrichment observed/expected (random) overlap (right)(units of fold) for each feature is given. 
b) Percentage of WT and Ames dwarf aDMRs that overlap with either histone modifications or 
panel of 30 transcription factors (Histone or TF) (blue) or neither (Neither)(red). c) Venn 
diagram of the base pair (in mega bp) overlap between hypermethylated aDMR containing CpG 
islands and hypermethylated aDMR containing bivalent regions in Ames WT. Enrichment of 
overlap obs/exp 1302-fold, P<0.001. d) Kernel smoothed line plots of selected bivalent CpG 
island (CpGI) overlapping hypermethylated aDMRs, +/- 5kb. Replicates for 2 month WT (WTY) 
and 22 month WT (WTO) mice are represented by solid blue and dashed blue lines respectively. 
DMRs are shown in pink and CpGs black. H3K4me3 and H3K27me3 enrichment (ChIP-seq) is 
indicated. e) Venn diagram of liver bivalent regions that contain hypermethylated aDMRs in WT 
and dwarf mice. Enrichment of overlap obs/exp 173-fold, P<0.001. f) Mean number of 
hypermethylated bivalent aDMRs per gene for WT (Blue) and Ames dwarf (Red). Genes are split 
into quartiles by expression (Q1 = highest, Q4 = lowest). Unexpressed genes (FPKM = 0) are given 
(U). 
 
Figure 5. Ames dwarf mice are resistant to cancer-like methylation changes during aging. 
a) Mean methylation enrichment per probe (top panel) at all probes within enhancers that 
contain WT hypomethylated aDMRs, for control (x-axis) and Mdr-2 knock out (y-axis) mice.  
Numbers top left and bottom right show the number of probes above and below the dashed 
diagonal. Bottom panel shows same data per mouse replicate. P<0.05 indicated by * (two tailed t-
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test). b) as a), however using enhancers containing WT  hypermethylated aDMRs. P<0.01 
indicated by ** (two tailed t-test). c) as a), however using bivalent regions that contain Ames WT 
hypermethylated aDMRs. P<0.01 indicated by ** (two tailed t-test). d) as a), however using 
enhancers that contain Ames dwarf hypomethylated aDMRs. P>0.05 (two tailed t-test). e) as a), 
however using enhancers that contain Ames dwarf  hypermethylated aDMRs. P<0.01 indicated by 
** (two tailed t-test). f) as a), however using bivalent regions that contain Ames dwarf 
hypermethylated aDMRs. P<0.01 indicated by ** (two tailed t-test).  
 
Figure 6. Age-associated DNA methylation changes are also suppressed by calorie 
restriction and rapamycin. a) Global % methylation per sample, for 2 month (Y) and 22 month 
(O) control, 22 month caloric restricted (CR) and 22 month Rapamycin treated (Rapa) UM-HET3 
mice. Part of this panel is reproduced from Figure S1c. All P>0.05 (two tailed t-test on arcsine 
transformed proportions). b) Mean % methylation per sample across all O-Y hypomethylated 
aDMRs for the samples in a). Y vs O, Y vs Rapa, O vs CR all P<0.001 (selected indicated by **) and 
Y vs CR, O vs Rapa , CR vs Rapa all P<0.05 (selected indicated by *) (two tailed t-test on arcsine 
transformed proportions). c) Mean % methylation per sample across all O-Y hypermethylated 
aDMRs for the samples in a). Y vs O, Y vs Rapa, Y vs CR, all P<0.001 (selected indicated by **), O vs 
CR, CR vs Rapa P<0.05, O vs Rapa P>0.05 (selected indicated by *) (two tailed t-test on arcsine 
transformed proportions). d) Clustered feature interaction maps of spatial overlap between O-Y 
aDMRs (columns) and a selection of genomic, histone and transcription factor features (rows), 
showing hypomethylated aDMRs that are also CR-O hypermethylated DMRs (i.e. suppressed by 
CR). 1116 regions. e) As d), for O-Y hypermethylated aDMRs that are also CR-O hypomethylated 
DMRs (i.e. suppressed by CR). 359 regions. f) As d), for O-Y hypomethylated aDMRs that are also 
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Rapa-O hypermethylated DMRs (i.e. suppressed by rapamycin). 330 regions. g) As d), for O-Y 
hypermethylated aDMRs that are also Rapa-O hypomethylated DMRs (i.e. suppressed by 
rapamycin). 225 regions. In d)-g), interaction map x axes are scaled by number of aDMRs. h). 
Composite profiles of mean percent methylation at all hypomethylated aDMR (Old-Young, UM-
HET3 mice) enhancer regions (n=1867), showing Young (blue), Old (black), CR (orange) and 
rapamycin (red). i) Composite profiles of mean percent methylation at hypermethylated aDMR 
(Old-Young) bivalent regions (n=536), showing Young (blue), Old (black), CR (orange) and 
rapamycin (red).   
 
Figure S1. Supplementary data to Figure 2. a) Global % methylation per sample, for 2 month 
(Y), 22 month (O) UM-HET3 mice. P>0.05 (two tailed t-test on arcsine transformed proportions). 
b) Principal component analysis of Bisulphite sequencing % methylation, for Y and O UM-HET3 
mice. c) Venn diagrams of overlap in mega bp between WT and dwarf hypermethylated aDMRs 
(left) and hypomethylated aDMRs (right). Both WT and dwarf, P < 0.001. d) Mean % methylation 
per sample across all hypermethylated aDMRs that present in WT but not dwarf mice. WTY vs 
WTO, WTY vs DY, WTO vs DO P<0.001 indicated by ** and DY vs DO P>0.05 (two tailed t-test on 
arcsine transformed proportions). e) Mean % methylation per sample across all 
hypermethylated aDMRs that present in dwarf but not WT mice. DY vs DO, WTO vs DO P<0.001 
indicated by **, WTY vs DY P<0.05 indicated by *, WTY vs WTO P>0.05 (two tailed t-test on 
arcsine transformed proportions). f) Mean % methylation per sample across all hypomethylated 
aDMRs that present in WT but not dwarf mice. WTY vs WTO, WTO vs DO P<0.001 indicated by **, 
DY vs DO P<0.05 indicated by *, WTY vs DY P>0.05 (two tailed t-test on arcsine transformed 
proportions). g) Mean % methylation per sample across all hypomethylated aDMRs that present 
 32 
in dwarf but not WT mice. DY vs DO, WTY vs DY P<0.001 indicated by **, WTY vs WTO P<0.05 
indicated by *, WTO vs DO P>0.05 (two tailed t-test on arcsine transformed proportions). h) Left 
panel : Scatter plot of all hypomethylated aDMRs common to both WT and Ames dwarf mice, 
showing mean % methylation (per region) in 2 month old WT mice (y-axis) and 2 month old 
dwarf mice (x-axis). Regions that are significantly different in % methylation between WT and 
dwarf are shown in red. Right panel : As left, but in old mice.  
 
Figure S2: Supplementary data to Figure 3. a) Clustered feature interaction maps of spatial 
overlap between hypomethylated aDMRs (columns) and a panel of 30 transcription factors 
(rows), showing WT (WT)(left) and dwarf (D)(center left) aDMRs. Red indicates an overlap 
between aDMR and feature and blue no overlap. Interaction map x axes are scaled by number of 
aDMRs. The % overlap (center right) and fold enrichment observed/expected (random) overlap 
(right)(units of fold) for each feature is given. b) Proportion of enhancers overlapping WT (outer 
ring) and dwarf (inner ring) hypomethylated aDMRs that are: promoter (blue), genic (and not 
promoter)(red) and intergenic (and not promoter)(green). c) Mean difference in % methylation 
(22 month (O) – 2 month (Y)) per CpG within hypomethylated aDMRs that overlap genic 
enhancers. CpGs are split into quartiles by expression of the nearest gene (Q1 = highest, Q4 
lowest). Unexpressed genes (FPKM = 0) are given (U). WT (blue) and dwarf (red) values are 
shown. d) Mean percent of gene that is a hypomethylated aDMR that overlaps genic enhancers 
for WT (Blue) and Ames dwarf (Red). Genes are split into quartiles by expression (Q1 = highest, 
Q4 = lowest). Unexpressed genes (FPKM = 0) are given (U). WT (blue) and dwarf (red) values are 
shown. e) Mean size in bp that is a hypomethylated aDMR that overlaps genic enhancers for WT 
(Blue) and Ames dwarf (Red). Genes are split into quartiles by expression (Q1 = highest, Q4 
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lowest). Unexpressed genes (FPKM = 0) are given (U). WT (blue) and dwarf (red) values are 
shown. f) Most highly enriched tissue expression profiles (David, UP tissue) amongst all WT (top 
table) and dwarf (bottom table, italicized) genes with aDMR overlapping enhancers.  
 
Figure S3. Supplementary data to Figure 4. a) Clustered feature interaction maps of spatial 
overlap between hypermethylated aDMRs (columns) and a panel of 30 transcription factors 
(rows), showing WT (WT)(left) and dwarf (D)(center left) aDMRs. Red indicates an overlap 
between aDMR and feature and blue no overlap. Interaction map x axes are scaled by number of 
aDMRs. The % overlap (center right) and fold enrichment observed/expected (random) overlap 
(right)(units of fold) for each feature is given. b) Barchart of the number of WT (blue) and Ames 
dwarf (red) aDMRs that overlap with either histone modifications or panel of 30 transcription 
factors (TF and Histone) or neither (Neither). c) Histograms of number of hypermethylated 
aDMRs (y-axis) by % methylation (x axis) in 2 month WT (left) and Ames dwarf (right) mice. 
Showing aDMRs that overlap with either histone modifications or panel of 30 transcription 
factors (blue) or neither (red). d) Top enriched IPA molecular functions for all genes containing 
WT (left) and Ames dwarf (right) hypermethylated aDMRs overlapping bivalent regions.  
 
Figure S4: Supplementary data to Figures 2-4. a) Box-plot of mean MeDIP enrichment at 
shared hypermethylated aDMR bivalent regions.  We observe significant increase of mean 
enrichment across all regions with strain and age in both instances. WTY vs. WTO (P=0.011) and 
DY vs. DO (P=0.011) all P<0.05 indicated by *(significance was determined using a Mann-
Whitney test of median shift). b) Box-plot of mean MeDIP enrichment at a shared set of 
hypomethylated aDMR enhancer regions.  We observe significant decrease in enrichment in both 
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dwarf and WT strains with age. WTY vs. WTO and DY vs. DO all P<0.001 indicated by 
**(significance was determined using a Mann-Whitney test of median shift). 
 
Figure S5: Supplementary data to Figure 6. a) Bar chart of the number of significantly 
differentially methylated regions (5% FDR, Fisher’s Exact test, 500bp windows), between UM-
HET3 young (2 months) and old (22 month) control mice (Old-Young), young and 22 month 
calorie restricted mice (CR-Young) and young and 22 month Rapamycin treated mice (Rapa-
Young). Regions of heterogeneity (chi-squared test (<0.05) across the 4 replicates in each cohort 
removed. See also Supp Dataset 2. Hyper and Hypo-methylated DMRs are higher and lower in 22 
month mice respectively. b) Scatter plot of all hypomethylated aDMRs (significant as defined in 
a)) between 22 month (O) and 2 month (Y) control UM-HET3 mice, showing mean percent 
methylation (per region) in 22 month old control mice (x-axis) and 22 month old calorie 
restricted mice (CR)(y-axis). Regions that are significantly different in % methylation between 
control and CR mice are given in red. Only regions with >=10 reads in CR were included. c) As b), 
however using percent methylation in Rapamycin treated (Rapa) instead of CR. d) Histogram of 
hypomethylated aDMR (significant as defined in a)) counts (O-Y) versus relative difference in 
mean % methylation per aDMR, for: (O-Y)/Y (blue), (Rapa-Y)/Y (red) and (CR-Y)/Y (green). e) As 
b), however using all hypermethylated aDMRs between 22 month (O) and 2 month (Y) control 
mice. f) as b) however using all hypermethylated aDMRs between 22 month (O) and 2 month (Y) 
control mice, and % methylation in Rapamycin treated (Rapa) instead of CR. g) Histogram of 
hypermethylated aDMR  (significant as defined in a)) counts (O-Y) versus relative difference in 
mean % methylation per aDMR, for: (O-Y)/Y (blue), (Rapa-Y)/Y (red) and (CR-Y)/Y (green). h) 
Left : Clustered feature interactions maps of spatial overlap between DMRs (significant as defined 
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in a)) that are hypomethylated in CR-Young but not Old-Young. Red indicates an overlap between 
DMR and feature and blue no overlap. 1301 regions. Other 3 interaction maps as indicated. 
Interaction map x-axes are scaled by number of DMRs indicated.  
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